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tal budget impact with this new procedure incorporation under the SUS perspec-
tive. Methods: The BIA was based on a Markov model with quarterly cycles and 
5-year time horizon in order to predict clinical and economic outcomes in a scenario 
with TAVI incorporation compared to the actual scenario – drug therapy (amiodarone, 
furosemide and digoxin) with or without aortic balloon valvoplasty. Epidemiological 
data were obtained from DATASUS and survival was extrapolated from PARTNER 
cohort B trial by using a Weibull distribution. Resource use, also gathered from this 
trial, included early perioperative complications (30 days) and late events (rehospi-
talization, dialysis, stroke, pacemaker implantation and major vascular complica-
tions). Costs were taken from the official Brazilian public official lists (DATASUS and 
BPS). Market-share data was obtained from Sociedade Brasileira de Hemodinâmica e 
Cardiologia Intervencionista. Results: The estimated number of Brazilian patients 
eligible for SSVS treatment was 795, 922, 1,180, 1,335 and 1,402 respectively for years 1-5 
of analysis. Compared to the current scenario, the inclusion of TAVI procedure with a 
13% market share during the analysis period shows an additional budget through year 
1-5 of 3.5M, 5.0M, 6.7M, 8.1M and 9.4M, consecutively. ConClusions: The incremental 
budget impact to include TAVI as a treatment option in the Brazilian Public Healthcare 
System for SSVS high-risk patients was estimated to be USD 65 million in 5 years.
PCV14
Análise De imPACto orçAmentário Do oClusor sePtAl PerCutâneo 
PArA o FeChAmento De ComuniCAção interAtriAl (CiA) Do tiPo ostium 
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objetivos: Analisar o impacto orçamentário do implante de oclusor septal per-
cutâneo para o fechamento de comunicação interatrial do tipo ostium secundumem 
comparação a cirurgia cardíaca convencional. Métodos: Análise sob a perspectiva 
do Sistema Único de Saúde (SUS) em um horizonte temporal de cinco anos, para 
uma população de pacientes portadores de CIA do tipo Ostium Secundum.O modelo 
considerou os custos com as intervenções durante o período de internação e a 
análise da incorporação do oclusor seguiu o pressuposto de uma taxa de utilização 
de 75% dos pacientes portadores de CIA OS. ResultAdos: Apresentou uma redução 
de mais de sete milhões de reais a favor da incorporação do oclusor percutâneo 
em relação a cirurgia como procedimento exclusivo. As análises de sensibilidade 
confirmaram uma economia favorecendo o oclusor percutâneo para o fechamento 
de CIA ostium secundum. E ao cruzar as variações de custos da cirurgia, do oclusor 
e das taxas de utilização para uma melhor aproximação da realidade, o resultado 
permaneceu favorável e demonstrou uma concentração do número de casos na 
faixa entre zero e R$40.000.000,00 em economia. ConClusões: A análise demon-
strou a possibilidade de redução dos custos para o fechamento de CIA do tipo ostium 
secundumcom a incorporação de uma tecnologia que já vem sendo bem indicada 
e utilizada ao longo dos últimos 36 anos, como uma alternativa segura e eficaz ao 
fechamento cirúrgico tradicional. O implante de oclusor septal percutâneo é uma 
opção repleta de méritos ao evitar que o paciente sofra os traumas físicos e riscos 
associados ao procedimento cirúrgico, bem como os riscos psicológicos causados 
pela estética gerada pela cicatriz cirúrgica e trauma da internação para as crianças.
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objeCtives: To develop cost-effectiveness analysis of collagenase (CO) versus 
hydrogel (HG) dressings for chronic-wound treatment in adults, under the per-
spective of Brazilian public payers. Methods: Data from the Brazilian Hospital 
Information System from January 1st to December 31st 2012 was used to deﬁne the 
annual number of hospital admissions due to chronic wounds (only non-surgical 
records with L89 ICD-10 code included). The model assumed that CO is the current 
practice in Brazilian public hospitals and patients are discharged at the time their 
wound heals. The difference in MHT was applied to the average length of stay 
(LOS) reported in the database. Resource use was estimated through expert panel 
and unit costs were obtained from Brazilian ofﬁcial price lists. Results: A total 
of 280,440 hospitalizations were identiﬁed with mean LOS of 4.47 days. The model 
estimated costs for the inpatient period assuming one dressing change for CO and 
HG. The cost per dressing change was estimated as 13.83BRL for CO and 11.95BRL 
for HG and the overall treatment costs were 61.82BRL and 53.42BRL according to the 
LOS. HG-related incremental costs were -8,40BRL indicating a cost-saving proﬁle. 
Addopting HG as wound management protocol would save 527,227.20BRL for the 
2012 cohort. Beneﬁts in terms of reduction in LOS were not accounted in the base 
case scenario. ConClusions: HG dressing has shown higher efﬁcacy when com-
pared to CO dressings, with fewer costs. The clinical and economic incremental 
results between different dressings reinforce the need of evidence-based decision 
making and rational resource allocation.
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objeCtives: The present study determined the total direct health-care costs for the 
management of PAH patients with differing degrees of disease severity. The study 
also aimed to find the key cost drivers in the management of PAH. Methods: PAH 
patients were recruited from a tertiary care hospital between January 1, 2009 and 
total consumption of all drugs from the C group. Total consumption of drugs acting 
on the renin-angiotensin system (C09) in Serbia in opserved period was over 41 
% of the total consumption of all drugs from the C group. The highest percentage 
in this group belonged to the ACE inhibitors. Consumption of angiotensin recep-
tor inhibitors is small and it is only a few percent of the total consumption of all 
drugs from C09 group. However, consumption of drugs in this subgroup recorded 
steady growth in recent years. ConClusions: In Serbia in the observed period, 
ACE inhibitors are the most frequently used drugs within the group of drugs which 
is used for treatment of hypertension. This research was supported by Provincial 
Secretariat for Science and Technological Development, Autonomous Province of 
Vojvodina project No 114-451-2458/2011 and by Ministry of Science, Republic of 
Serbia, project no 41012.
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objeCtivos: Estimar el impacto en discapacidad y económico del incremento de 
utilización de trombolisis para el manejo agudo de ictus isquémico (IS) en Chile, 
aplicando un modelo de simulación de eventos discretos. MetodologíAs: Se mod-
eló la historia natural y el manejo agudo de los IS para población adulta chilena, 
incorporando tiempos desde el inicio de síntomas al tratamiento y cuatro escenarios 
de utilización de trombolisis: a) utilización actual (1,7%), b) utilización de 11,6% 
tratando todos los pacientes que son atendidos dentro de la ventana terapéutica, 
c) 25% de utilización, y d) 100% de utilización. Se usaron distribuciones empíricas 
y teóricas para incluir la probabilidad y tiempos de los eventos. Se realizó una 
simulación entre 2002-2017, usando el software ARENA. Los resultados fueron la 
prevalencia de discapacidad por escenario. Se realizó un análisis de impacto pre-
supuestario desde la perspectiva del asegurador público de salud, considerando los 
costos directos del tratamiento y de rehabilitación. ResultAdos: En 2017 man-
teniendo la actual utilización de trombolisis (1,7%), la tasa de prevalencia por IS es 
360,8 por 100.000 habitantes, presentando una disminución entre los escenarios, 
siendo 299,8 cuando todos los pacientes son tratados. Con respecto a la utilización 
actual, aumentar el tratamiento al 11,6% evita 779 discapacitados, al 25% evita 
1.783 y tratar a todos los pacientes evita 8.534. A lo largo de la simulación, los costos 
ahorrados por casos de rehabilitación evitados son más bajos que los costos de la 
trombolisis. ConClusiones: La tasa de prevalencia de discapacidad disminuye 
moderadamente al incrementar la utilización de trombolisis. El impacto poblacional 
en discapacidad manteniendo la utilización actual es marginal, siendo recomenda-
ble incrementar su utilización. Los costos directos aumentarían por sobre el costo de 
rehabilitación evitados, sin embargo, es necesario considerar la limitada cobertura 
de atención de la discapacidad en Chile y los costos sociales.
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objeCtives: There is no enough data available in our country about the preva-
lence of risk factors for ST elevation myocardial infarction (STEMI) and which has 
the highest mortality rate in hospitals of Pakistan. The purpose of study was to 
access the age distribution, location of infarct, risk factors, sign & symptoms and 
in-hospital management of STEMI patients in Bahawalpur region, southern Punjab, 
on of the regions with high risk of coronary heart disease. Methods: A retrospec-
tive study of 400 patients diagnosed as STEMI admitted to Bahawal Victoria Hospital 
(BVH), Bahawalpur, Southern Punjab, Pakistan was done by following their hospital 
record. Results: The mean age of STEMI patients were 40 ±10. Smoking, Diabetes 
and Hypertension were the risk factors (51.5%), (28%), (20.5%) respectively. Anterior 
wall Myocardial infarctions were seen (51.5%). Sweating, vomiting, shortness of 
breath (SOB) & nausea accounted for more than 60% of the symptoms with chest 
pain mostly in left arm. Among the patients who reached early to hospital & received 
Streptokinase (SK) were 150 (75%), those late for SK were 44(22%), thrombolytic 
therapy was contraindicated only in 6 (3%) patients. Most prescribed medication 
are aspirin (100%), clopidogrel (98%), statin (96%), ACE-I (77.5%), nitrates (69.5%), 
beta blocker (60%), anticoagulant (50%), LMW-heparin (33 %). ConClusions: The 
result of our study, in which the risk factors especially smoking were found to have 
a prevalence in patients with STEM1 living in southern Punjab, suggested that STEM 
1 can be prevented by the modification of these risk factors.
CArDioVAsCulAr DisorDers – Cost studies
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A buDget imPACt AnAlysis (biA) oF trAnsCAtheter AortiC VAlVe 
imPlAntAtion (tAVi) in high-risk PAtients With syntomAtiC seVere 
VAlVe stenosis (ssVs) unDer the brAziliAn PubliC heAlth CAre system 
(sus) PersPeCtiVe
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objeCtives: Aortic valve stenosis is a progressive valvular heart disease with a stand-
ard care that involves a major open surgery. However, part of the patients is ineligible 
for surgery, therefore drug therapy is the only option available. Once TAVI is a less 
invasive surgical option, clinical trials demonstrated significant benefits, although 
procedure and device are costly. The aim of this study was to estimate the incremen-
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each generic was used to estimate one month’s cost of hypertension treatment; 
considering the maximum and minimum dosage for each generic. The affordability 
of treatments was calculated by comparing the total cost of medicines to the daily 
official minimum wage ($63.12MXN, 2013 prices) Results: The number of days’ 
wages required to pay one month of antihypertensive therapy ranged from: 0.08-
4.18 for diuretics, 0.67-1.90 for beta blockers, 1.7-3.99 for calcium channel blockers, 
0.71-3.31 for ACE inhibitors and 2.38-8.11 for ARBs. ConClusions: Cost could be 
a substantial barrier for permanence in antihypertensive treatment, so that should 
be discussed measures to prevent this from happening.
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treAtment Costs oF isChemiC stroke PreVention AnD mAnAgement 
in PAtients With AtriAl FibrillAtion (AF) in lAtin AmeriCA: ArgentinA, 
brAzil, Chile, AnD VenezuelA
Soriano M.A.1, Leyva-Bravo V.1, González-Rojas G.L.1, Medina-Farina M.2, Duarte M.A.3
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objeCtives: AF is the most common chronic cardiac arrhythmia worldwide. Most 
patients with AF need life-long treatment to be protected from ischemic stroke. The 
aim was to conduct a high level cost assessment for stroke prevention and manage-
ment in patients with AF [SPAF & SMAF] in 4 Latin American countries. Methods: 
Overall the costs of SPAF & SMAF were determined through 59 face-to-face interviews 
with cardiologists in Argentina, Brazil, Chile and Venezuela. Treatment costs were 
estimated using benchmarks from major private and public hospitals in each coun-
try. Results: On average, the largest component of real-life medical expenditures 
for SPAF, under appropriate treatment given CHADS2 scores, was prescription drugs, 
which ranged from 68% in private to 75% in public. Annual SPAF treatment ranged in 
price from US$425 in Argentina to US$1,935 in Chile in private institutions and US$85 
in Brazil to US$1,199 in Venezuela in public institutions. Moreover, overall treatment 
costs in Chile were 5X higher than the least expensive country in each sector. For 
SMAF, using rivaroxaban vs the common Vitamin K antagonists resulted in a 24%-46% 
cost reduction for disease treatment at a national level due to better patient adher-
ence. This would decrease the stroke incidence/year, which would translate to US$143 
M /yr in savings. ConClusions: AF is an important source of health care resource 
utilization because of repeated medical examinations, extensive use of laboratory 
tests and pharmacological treatments. Private and public institution cost differences 
are common in all 4 countries. Improving access to novel drugs, such as rivaroxaban, 
could help improve cost allocation, inducing a savings opportunity in each country.
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objeCtives: Catheter-based renal denervation (RDN) is a new therapy for resistant 
hypertension, a condition that affects approx. 10-15% of hypertensive patients, in 
which blood pressure is uncontrolled despite the simultaneous use of three or more 
antihypertensive drugs. Our objective was to assess clinical and cost-effectiveness 
of RDN compared to standard of care (SoC) from the Mexican public payer per-
spective. Methods: A previously published lifetime Markov model was adapted 
to the Mexican setting to predict clinical endpoints (death, myocardial infarction, 
stroke, heart failure, coronary heart disease, end-stage renal disease) and costs - 
based on Mexican epidemiological and cost data. We evaluated the impact of a 
32 mmHg reduction in systolic blood pressure, from a baseline of 178 mmHg, in 
a 58-year old 43% female, 34% diabetic, and 16% smoking cohort, as observed in 
the Symplicity HTN-2 randomized controlled trial. Direct public health care costs 
were estimated from the published literature and from governmental databases. 
The incremental cost-effectiveness ratio (ICER) was computed as incremental costs 
per life-year gained, discounted at 3%. Deterministic sensitivity analyses were 
performed. Results: RDN was projected to reduce cardiovascular endpoints by 
22-32% over 10 yrs., and 7-17% over lifetime. The lifetime ICER was estimated at 
MXN$ 194,128 (US$ 14,750) per LY gained, and had an incremental cost of MXN$ 
117,916 (US$ 8,959) compared to SoC. Application of higher discount rates led to 
a measured increase in the ICER. ConClusions: Our model projections suggest 
that RDN reduces and delays cardiovascular events and is a cost-effective therapy 
in Mexico when considering most international willingness-to-pay thresholds, but 
remains above the current national government threshold of one GDP/capita of 
MXN$ 139,900 (US$ 10,630) per additional life year.
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objeCtives: Aortic stenosis is the most common valvular heart disease in the elderly 
– its prevalence is estimated to be up to 5% in individuals over 75 years. Surgical 
replacement of the aortic valve is considered the standard care and in the absence 
of serious coexisting conditions, the procedure is associated with low operative mor-
tality. However, a significant proportion of patients can not undergo surgery due to 
a high surgical risk associated with advanced age or with the presence of multi-
ple coexisting conditions. Treatment with transcatheter aortic-valve implantation 
(TAVI) is a therapy with potentially lower peri-procedure risk and has been used as 
a therapeutic option in this group of patients considered inoperable. Therefore, this 
study aims to develop a cost-effectiveness analysis of TAVI in patients with severe 
aortic stenosis who are not suitable for surgical treatment. Methods: A Markov 
model was developed to compare the TAVI versus standard therapy (drug treatment 
2011. One-year costs were identified by applying cost data to medical informa-
tion obtained by review of medical records. Costs included those for medications, 
laboratory and diagnostic tests, clinic visits, emergency room visits and hospital 
stays. Contemporary data were obtained from epidemiological studies, government 
datasets, and other sources to estimate prevalence. National costs (US dollar 2012) 
of treatment for PAH were estimated by extrapolation of mean cost estimate per 
person to national incidence data for PAH. Because of uncertainties surrounding 
some of our estimates such as prevalence, one way sensitivity analyses were under-
taken. Results: A total of 113 PAH patients were identified and their demographic 
and clinical characteristics, patterns of care were examined. The mean age was 38 
years, and 83% were female. The average per patient annual cost was $ 10,869 with-
out specific treatment (min $ 137; max $155,928). The annual cost for the treatment 
of a single PAH patient per year with specific therapy (Bosentan) was calculated in 
$31.433. Aggregate national health care expenditures for treatment of PAH were 
USD 46.6 million In multivariate analysis, length of hospital stay, stay in ICU, were 
all significant independent predictors of treatment. ConClusions: There is a cor-
relation between the cost of HAP and disease severity with hospitalization owing 
to disease severity being a major contributor to cost. With the expected increase in 
the incidence of PAH in Mexico over the coming decades, these results emphasize 
the need for effective preventive and acute medical care.
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objeCtives: To estimate the procedure (implantation) cost, the total hospitalization 
cost and annual follow-up cost, in patients subjected to pacemaker (PM) and implant-
able cardioverter-defibrillator (ICD) implantation. Methods: A single-center, pro-
spective, cost-of-illness study was conducted between August 2008 and July 2009. In 
total, 464 consecutive patients were recruited (370 were subjected to PM implantation 
and 94 to ICD implantation). Resource data were assessed at patients’ enrolment in 
the study and at 6th and 12th months of patients’ follow-up. Then, the procedure cost, 
the total hospitalization cost as well as the annual patients’ follow up costs were cal-
culated using a bottom-up approach. Results: The mean (95% confidence interval) 
procedure cost of PM and ICD implantation (including the costs of devices, electrodes, 
other supplies, and personnel’s time) was calculated to be € 1803 (€ 1758–€ 1858) and 
€ 13 521 (€ 13 153–€ 13 892), respectively. The mean total hospitalization cost (includ-
ing procedure cost, hospitalization cost, cost of laboratory and imaging diagnostic 
examinations and the indirect cost attributed to productivity lost due to patient’s 
hospitalization) was € 3926 (€ 3711–€ 4167) for PM and € 17 764 (€ 16 852–€ 18 692) for ICD. 
The mean annual cost (direct and indirect) was € 1816 (€ 1433–€ 2421) for PM and € 2819 
(€ 2115–€ 3703) for ICD. No difference was detected in the annual cost between patients 
with initial implantation and replacement. ConClusions: These data revealed that 
although these devices are associated with a relatively high upfront cost, the annual 
societal cost following the implantation is low. Therefore, implantation of such devices 
should be encouraged since these devices reduce the morbidity and mortality without 
a high economic burden to society.
PCV18
eConomiC burDen oF CoronAry heArt DiseAse in the PAtients 
AttenDing nAtionAl heArt Center, kAthmAnDu, nePAl
Dangi A.1, Lohani S.P.2
1Nobel College, Pokhara University, Kathmandu, Nepal, 2Center for Health Research and 
International Relations, Nobel College, Pokhara University, Kathmandu, Nepal
objeCtives: To calculate cost of illness due to coronary heart disease in the patients 
attending National Heart Center, Kathmandu, Nepal. Methods: Descriptive cross 
sectional survey was conducted. The total number of sample was 120. The sam-
ple was selected by non-probability purposive sampling method. Data entry and 
analysis was done using SPSS 16.0. Categorical variables were compared using 
Independent Sample t-test and cross tabulation was done and chi- square test was 
applied to show significant difference between variables. Results: Agriculture was 
the main source of income of the coronary heart disease household and the aver-
age annual household income was NRs. 1, 54,000 (US $ 1792). The study estimated 
the average cost of illness to be NRs. 30,888.14 (US $ 360) for an outpatient episode 
of coronary heart disease which was 20.05% of the average annual income of CHD 
household. The average total time loss of the CHD household was 8.75 person days. 
The average total direct cost was NRs. 29,600 (US $ 344) of which medical cost was 
the largest component. The average monetary value of time loss by the household 
was found to be 2,981.18 (US $ 35). ConClusions: The study found high cost of 
illness due to centralised system of health care.The findings of the study showed 
that households struggled to cope and adopted unsustainable strategies that dam-
aged asset and caused or sustained impoverishment. Thus, estimated cost appears 
to be sustained economic burden on the individual household.
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objeCtives: Hypertension (HT) is one of the most prevalent chronic diseases in 
Mexico. In the last two decades, a substantial increase in the prevalence of HT was 
observed in Mexico from 25% in 1993 to 43.2% in 2006 in adult population (≥ 20 
years old). Almost 50% of population is not under a social security scheme and 
many patients pay for medicines out-of-pocket. This study’s aim was to calculate 
the affordability of different kinds of antihypertensive drugs in Mexico. Methods: 
Price data for 5 classes of antihypertensive drugs (diuretics, beta blockers, calcium 
channel blockers, ACE inhibitors and angiotensin II receptor antagonists or ARBs) 
were obtained from public internet sources, and the lowest price identified for 
